Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
November 03, 2023 10:46 ET
|
Travere Therapeutics, Inc.
“The totality of data from the PROTECT study demonstrates FILSPARI is effective, safe and has an important place in the IgAN treatment landscape ..."
Point of Care Molecular Diagnostics Market Worth $5.38 Billion by 2028 - Exclusive Report by The Insight Partners
October 30, 2023 05:27 ET
|
The Insight Partners
Pune, India, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Point-of-care molecular diagnostics include portable devices, and assays & kits used to detect and diagnose diseases in human samples, such as...
Quanta Therapeutics Presents Late-Breaking Data for QTX3034, a multi-KRAS inhibitor, at AACR-NCI-EORTC Conference
October 11, 2023 12:00 ET
|
Quanta Therapeutics, Inc.
The combination of QTX3034, a multi-KRAS inhibitor, and EGFR inhibitors demonstrated potent, synergistic anti-tumor activity in preclinical studies.
EGFR Tests Market Report: Quantitative Trends, Regulatory Dynamics, and Future Projections
September 06, 2023 05:53 ET
|
Research and Markets
Dublin, Sept. 06, 2023 (GLOBE NEWSWIRE) -- The "EGFR Tests Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and...
Dignity Health St. Joseph’s Hospital and Medical Center launches new initiative to address health disparities of African Americans with chronic kidney disease
February 27, 2023 16:08 ET
|
Dignity Health St. Joseph's Hospital and Medical Center
PHOENIX, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Dignity Health St. Joseph’s Hospital and Medical Center has launched a new initiative to address race-based algorithms in early diagnosis of chronic kidney...
Liquid Biopsy Global Market Report 2022: Increased Government Funding for Cancer Detection Drives Growth
November 15, 2022 08:33 ET
|
Research and Markets
Dublin, Nov. 15, 2022 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Global Market Report 2022, By Product, By End User, By Clinical Application" report has been added to ResearchAndMarkets.com's offering....
Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients
December 16, 2021 06:30 ET
|
Cullinan Oncology, Inc.
CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID Continued high response rate with favorable safety and tolerability profile observed in...
Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients
December 13, 2021 07:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies,...
Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China
November 09, 2021 08:00 ET
|
Zai Lab Limited; Blueprint Medicines
-- Zai Lab obtains exclusive rights to develop and commercialize BLU-945 and BLU-701 in Greater China -- -- Collaboration accelerates and expands global development of Blueprint Medicines’...
Sorrento Enters Into Binding Term Sheet to Acquire Exclusive Rights to Abivertinib with Completed Registrational Trial Data in Non-Small Cell Lung Cancer
May 21, 2020 07:00 ET
|
Sorrento Therapeutics, Inc.
Novel TKI compound with dual selective targeting of mutant forms of EGFR and BTKMore than 600 patients have been treated with the compound across studies, with over 200 patients in the completed...